COMP <GO>
BIO vs UNH // RETURN ON INVESTED CAPITAL (ROIC)
Bio-Rad Laboratories Inc. (NYSE) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: BIO 4
— UNH 10
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: UNH
LAST: $372.18 (-3.18%) • MKT CAP: $10.28B
roic
0.50%
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
roic
11.47%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BIO VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BIO | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 51.90% | 88.57% | -36.67 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 0.50% | 11.47% | -10.97 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | 60.4x | 16.4x | +43.95 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 3.64% | 6.48% | -2.84 | UNH | /fcf-yield <GO> |
| Operating Margin | 1.80% | 4.82% | -3.02 | UNH | /operating-margins <GO> |
| Net Profit Margin | 29.40% | 3.14% | +26.26 | BIO | /net-margins <GO> |
| Revenue Growth (YoY) | 0.70% | 6.46% | -5.76 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.59 | 3.12 | +0.47 | BIO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.00% | 6.74% | +0.26 | UNH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.6 | 56.0 | -4.49 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.04 | 0.33 | +0.71 | BIO | /macro-sensitivity <GO> |
| Forward P/E Multiple | 12.6x | 17.1x | -4.49 | BIO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $10.28B | $364.66B | -$354.38B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BIO REV | UNH REV | BIO GROSS % | UNH GROSS % | BIO FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $2.58B | $447.57B | 51.9% | 88.7% | $374.6M | $16.07B |
| FY 2024 | $2.57B | $400.28B | 53.7% | 88.3% | $289.6M | $20.70B |
| FY 2023 | $2.67B | $371.62B | 44.0% | 89.6% | $254.7M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BIO // BETA 1.04
UNH // BETA 0.33